Email Alerts Required fields denoted by an asterisk (). Alert type Quote SEC Filing Event News Weekly Summary Email Leave this field blank
Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness
Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile
Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology
Innovation is the Best Medicine: How CEO Shane Schaffer and Cingulate Developed “Precision Timed Release,” a New Drug Delivery Platform for ADHD
Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301
